No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 20.500
- +0.260+1.28%
Close May 22 16:00 ET
- 20.520
- +0.020+0.10%
Post 19:30 ET
1.42BMarket Cap-6327P/E (TTM)
20.865High19.940Low635.85KVolume20.100Open20.240Pre Close12.98MTurnover1.16%Turnover RatioLossP/E (Static)69.15MShares58.38052wk High1.68P/B1.12BFloat Cap11.25052wk Low--Dividend TTM54.76MShs Float58.380Historical High--Div YieldTTM4.57%Amplitude7.520Historical Low20.416Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Akero Therapeutics Is Maintained at Outperform by Evercore ISI Group
Akero Therapeutics Is Maintained at Outperform by Evercore ISI Group
Express News | Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38
Express News | Akero Therapeutics Inc : Evercore ISI Cuts Target Price to $38 From $50
Akero Therapeutics Is Maintained at Buy by Canaccord Genuity
Akero Therapeutics Is Maintained at Buy by Canaccord Genuity
Akero Therapeutics Price Target Cut to $56.00/Share From $59.00 by Canaccord Genuity
Akero Therapeutics Price Target Cut to $56.00/Share From $59.00 by Canaccord Genuity
Insiders Could Have Profited By Holding Onto Akero Therapeutics Shares Despite 11% Drop
Akero Therapeutics, Inc.'s (NASDAQ:AKRO) value has fallen 11% in the last week, but insiders who sold US$4.7m worth of stock over the last year have had less success. Insiders might have been better
Comments
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
6
$Akero Therapeutics(AKRO.US$ Im done with medical stocks not a single one of these companies can make good decisions
$Akero Therapeutics(AKRO.US$ MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have made regarding its business operations and prospects.
Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on Akero's representations...
Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on Akero's representations...
$Akero Therapeutics(AKRO.US$ this been falling everday smh
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg